A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer
Abstract Background Pyroptosis can not only inhibit the occurrence and development of tumors but also develop a microenvironment conducive to cancer growth. However, pyroptosis research in prostate cancer (PCa) has rarely been reported. Methods The expression profile and corresponding clinical data...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-02-01
|
| Series: | BMC Medical Genomics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12920-022-01172-5 |
| _version_ | 1819274950227263488 |
|---|---|
| author | Ding Hu Qingfei Cao Ming Tong Chundong Ji Zizhi Li Weichao Huang Yanyang Jin Guangquan Tong Yutao Wang Pengfei Li Huashan Zhang |
| author_facet | Ding Hu Qingfei Cao Ming Tong Chundong Ji Zizhi Li Weichao Huang Yanyang Jin Guangquan Tong Yutao Wang Pengfei Li Huashan Zhang |
| author_sort | Ding Hu |
| collection | DOAJ |
| description | Abstract Background Pyroptosis can not only inhibit the occurrence and development of tumors but also develop a microenvironment conducive to cancer growth. However, pyroptosis research in prostate cancer (PCa) has rarely been reported. Methods The expression profile and corresponding clinical data were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Patients were divided into different clusters using consensus clustering analysis, and differential genes were obtained. We developed and validated a prognostic biomarker for biochemical recurrence (BCR) of PCa using univariate Cox analysis, Lasso-Cox analysis, Kaplan–Meier (K–M) survival analysis, and time-dependent receiver operating characteristics (ROC) curves. Results The expression levels of most pyroptosis-related genes (PRGs) are different not only between normal and tumor tissues but also between different clusters. Cluster 2 patients have a better prognosis than cluster 1 patients, and there are significant differences in immune cell content and biological pathway between them. Based on the classification of different clusters, we constructed an eight genes signature that can independently predict the progression-free survival (PFS) rate of a patient, and this signature was validated using a GEO data set (GSE70769). Finally, we established a nomogram model with good accuracy. Conclusions In this study, PRGs were used as the starting point and based on the expression profile and clinical data, a prognostic signature with a high predictive value for biochemical recurrence (BCR) following radical prostatectomy (RP) was finally constructed, and the relationship between pyroptosis, immune microenvironment, and PCa was explored, providing important clues for future research on pyroptosis and immunity. |
| first_indexed | 2024-12-23T23:16:34Z |
| format | Article |
| id | doaj.art-dbdbb22e7ad04430a5b2c4eb53f0a7a9 |
| institution | Directory Open Access Journal |
| issn | 1755-8794 |
| language | English |
| last_indexed | 2024-12-23T23:16:34Z |
| publishDate | 2022-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Medical Genomics |
| spelling | doaj.art-dbdbb22e7ad04430a5b2c4eb53f0a7a92022-12-21T17:26:29ZengBMCBMC Medical Genomics1755-87942022-02-0115111710.1186/s12920-022-01172-5A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancerDing Hu0Qingfei Cao1Ming Tong2Chundong Ji3Zizhi Li4Weichao Huang5Yanyang Jin6Guangquan Tong7Yutao Wang8Pengfei Li9Huashan Zhang10Department of Urology, Jinzhou Medical University, The First Hospital of Jinzhou Medical UniversityDepartment of Urology, Jinzhou Medical University, The First Hospital of Jinzhou Medical UniversityDepartment of Urology, Jinzhou Medical University, The First Hospital of Jinzhou Medical UniversityDepartment of Urology, Affiliated Hospital of Panzhihua UniversityDepartment of Urology, Jinzhou Medical University, The First Hospital of Jinzhou Medical UniversityDepartment of Urology, Jinzhou Medical University, The First Hospital of Jinzhou Medical UniversityDepartment of Urology, Jinzhou Medical University, The First Hospital of Jinzhou Medical UniversityDepartment of Urology, Jinzhou Medical University, The First Hospital of Jinzhou Medical UniversityDepartment of Urology, China Medical University, The First Hospital of China Medical UniversityDepartment of Urology, Jinzhou Medical University, The First Hospital of Jinzhou Medical UniversityDepartment of Urology, Jinzhou Medical University, The First Hospital of Jinzhou Medical UniversityAbstract Background Pyroptosis can not only inhibit the occurrence and development of tumors but also develop a microenvironment conducive to cancer growth. However, pyroptosis research in prostate cancer (PCa) has rarely been reported. Methods The expression profile and corresponding clinical data were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Patients were divided into different clusters using consensus clustering analysis, and differential genes were obtained. We developed and validated a prognostic biomarker for biochemical recurrence (BCR) of PCa using univariate Cox analysis, Lasso-Cox analysis, Kaplan–Meier (K–M) survival analysis, and time-dependent receiver operating characteristics (ROC) curves. Results The expression levels of most pyroptosis-related genes (PRGs) are different not only between normal and tumor tissues but also between different clusters. Cluster 2 patients have a better prognosis than cluster 1 patients, and there are significant differences in immune cell content and biological pathway between them. Based on the classification of different clusters, we constructed an eight genes signature that can independently predict the progression-free survival (PFS) rate of a patient, and this signature was validated using a GEO data set (GSE70769). Finally, we established a nomogram model with good accuracy. Conclusions In this study, PRGs were used as the starting point and based on the expression profile and clinical data, a prognostic signature with a high predictive value for biochemical recurrence (BCR) following radical prostatectomy (RP) was finally constructed, and the relationship between pyroptosis, immune microenvironment, and PCa was explored, providing important clues for future research on pyroptosis and immunity.https://doi.org/10.1186/s12920-022-01172-5PyroptosisTCGAGEOProstate cancerPrognostic signatureImmune infiltration |
| spellingShingle | Ding Hu Qingfei Cao Ming Tong Chundong Ji Zizhi Li Weichao Huang Yanyang Jin Guangquan Tong Yutao Wang Pengfei Li Huashan Zhang A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer BMC Medical Genomics Pyroptosis TCGA GEO Prostate cancer Prognostic signature Immune infiltration |
| title | A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer |
| title_full | A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer |
| title_fullStr | A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer |
| title_full_unstemmed | A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer |
| title_short | A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer |
| title_sort | novel defined risk signature based on pyroptosis related genes can predict the prognosis of prostate cancer |
| topic | Pyroptosis TCGA GEO Prostate cancer Prognostic signature Immune infiltration |
| url | https://doi.org/10.1186/s12920-022-01172-5 |
| work_keys_str_mv | AT dinghu anoveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT qingfeicao anoveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT mingtong anoveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT chundongji anoveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT zizhili anoveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT weichaohuang anoveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT yanyangjin anoveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT guangquantong anoveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT yutaowang anoveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT pengfeili anoveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT huashanzhang anoveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT dinghu noveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT qingfeicao noveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT mingtong noveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT chundongji noveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT zizhili noveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT weichaohuang noveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT yanyangjin noveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT guangquantong noveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT yutaowang noveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT pengfeili noveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer AT huashanzhang noveldefinedrisksignaturebasedonpyroptosisrelatedgenescanpredicttheprognosisofprostatecancer |